Tracing virus-specific CD8+ T cell clonotype zonation and function in humans

This project aims to redefine the role and distribution of CD8+ T cells in viral immunity using single-cell technologies, focusing on their function against SARS-CoV-2 and informing future vaccine development.

Subsidie
€ 1.499.932
2022

Projectdetails

Introduction

The current Covid-19 pandemic highlights the need to gain a better understanding of the precise mechanisms that enable immune control of viral infections. Although it is established that CD8+ T cells are required to suppress viremia, most view these cells simply as "killer T cells," based almost exclusively on studies of blood.

Key Discoveries

I recently discovered that efficient immune control of HIV is mediated primarily by non-killer resident memory CD8+ T cells, whereas CD8+ T cells with high "killer instinct" are mainly confined to the vasculature. These observations force a reevaluation of how antiviral CD8+ T cells are distributed anatomically and function in the tissue spaces where most viruses replicate.

Research Objectives

Using cutting-edge single-cell technologies on unique paired tissue samples from human organ donors, my aim here is to challenge prevailing concepts in the field of adaptive immunology and reassess how and where CD8+ T cells actually target viruses in the human body.

  1. Reference Map Creation
    My group will first use single-cell barcoding techniques to establish a reference map of CD8+ T cell clones specific for multiple viruses across tissue sites.

  2. Functional Dissection
    We will then dissect this information to determine whether distinct resident memory CD8+ T cell clones and/or subsets exhibit differential antiviral functions across tissue sites.

  3. Mechanistic Approaches
    In parallel, we will use more mechanistic approaches to define the epigenetic imprints and functional properties of antiviral CD8+ T cells, aiming to determine to what extent these features are shaped by:

    • Subset fate
    • Anatomical location
    • The nature of the expressed T cell receptor

Emphasis on Covid-19

A specific emphasis throughout this project will be to translate the emerging knowledge to the field of Covid-19, aiming to understand how CD8+ T cells control SARS-CoV-2.

Conclusion

This ambitious but technically feasible project will establish a systematic foundation for future studies of antiviral T cells in humans and inform the development of more effective vaccine platforms to combat future viral threats.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.932
Totale projectbegroting€ 1.499.932

Tijdlijn

Startdatum1-6-2022
Einddatum31-5-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • KAROLINSKA INSTITUTETpenvoerder

Land(en)

Sweden

Vergelijkbare projecten binnen European Research Council

ERC Advanced...

Traitor-virus-guided discovery of antiviral factors

This project aims to use CRISPR/Cas9 technology with HIV-1 to uncover antiviral mechanisms, enhancing our understanding and control of viral pathogens for better prevention and therapy.

€ 2.339.875
ERC Consolid...

Activation and switch of fates in T lymphocytes.

This project aims to model the fate choices of naïve and memory CD8+ T cells using experimental immunology and systems biology to enhance vaccine design and improve responses to infections and cancer.

€ 2.625.000
ERC Advanced...

Imprinting and clonality of human NK cell memory

This project aims to uncover the signals and mechanisms behind the clonal memory of human NK cells to enhance their effector functions and identify new targets for anti-tumor therapies.

€ 2.372.750
ERC Starting...

Conventional Dendritic Cells – Ecology, Diversity, and Function

The project aims to explore the diverse roles of conventional dendritic cell subsets in T cell activation during different immune responses to enhance cancer therapies and vaccine efficacy.

€ 1.796.125
ERC Starting...

Interrogating RNA-protein interactions underlying SARS-CoV-2 infection and antiviral defense

This project aims to decode RNA-protein interactions in SARS-CoV-2 to understand its replication cycle and identify potential antiviral targets for treating viral diseases.

€ 1.500.000